CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number | Lead Group | Study Title | CIRB | Study Status |
|---|---|---|---|---|
| ANHL1522 | COG | A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP)-specific Cytotoxic T-Lymphocytes (LMP-TC, IND # 17068) in Pediatric Solid Organ Recipients (SOT) with EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PTLD) | Pediatric CIRB | Available to Open |
| ADVL0524 | COG | Phase II Trial of Ixabepilone (BMS-247550); an Epothilone B Analog; in Children and Young Adults with Refractory Solid Tumors | Pediatric CIRB | Completed |
| ACCL21C2 | COG | Prospective Cohort Study to Evaluate Immunologic Response Following COVID-19 Vaccination in Children, Adolescents and Young Adults with Cancer | Pediatric CIRB | Completed |
| ACCL1032 | COG | A Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Cisplatin: A Groupwide Phase III Study | Pediatric CIRB | Completed |
| PBTC-055 | PBTC | Phase I/II trial of Dabrafenib, Trametinib, and Hydroxychloroquine (HCQ) for BRAF V600E-mutant or Trametinib and HCQ for BRAF fusion/duplication positive or NF1-associated recurrent or progressive gliomas in children and young adults | Pediatric CIRB | Available to Open |
| ANBL19P1 | COG | A Pilot Study of Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination with Irinotecan and Temozolomide in the Post-Consolidation Setting for High-Risk Neuroblastoma | Pediatric CIRB | Available to Open |
| AALL0932 | COG | Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy) | Pediatric CIRB | Available to Open |
| AHOD04B1 | COG | Hodgkin Disease (HD) Banking Study | Pediatric CIRB | Completed |
| ALTE03N1 | COG | Key Adverse Events after Childhood Cancer | Pediatric CIRB | Available to Open |
| ACNS1723 | COG | A Phase 2 Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly-Diagnosed BRAFV600-Mutant High-Grade Glioma (HGG) (IND# 145355) | Pediatric CIRB | Available to Open |